April 24th 2025
A pilot study reveals a dual-length microneedle RF device effectively reduces neck wrinkles by 35%, enhancing skin hydration and elasticity with minimal downtime.
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Revolutionizing Atopic Dermatitis (RAD) Conference 2025
June 6-7, 2025
Register Now!
Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient
July 26, 2025
Register Now!
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management
View More
Burst CME: Targeted Therapy for Optimal Psoriasis Management
View More
Botox applications continue to expand
May 1st 2004Maui, Hawaii - Next-generation botulinum toxin treatments promise to improve problems ranging from smokers' lines to sweaty palms. However, such treatments aren't for novices - be they dermatologists or patients. "As Botox is now becoming more widely accepted and we're becoming more used to its application, we're finding new uses for it," said Kevin S. Pinski, M.D.
FDA gives nod; Hylaform joins ranks of fillers
May 1st 2004Santa Barbara, Calif. -- The U.S. Food and Drug Administration late last month granted approval for Inamed Corp.'s Hylaform (Hylan-B gel). The hyaluronic-acid-based dermal filler is indicated for injection into the deep dermis for correction of moderate-to-severe facial wrinkles and folds. The move, while expected, adds a few wrinkles of its own to the growing U.S. market for dermal fillers.
Botox has long duration of action for Tx of axillary hyperhidrosis
May 1st 2004Washington - Intradermal botulinum toxin type A (Botox) for the treatment of primary axillary hyperhidrosis produces a durable effect, with nearly half of patients requiring only one treatment over a one-year period, according to study data released at the annual meeting of the American Academy of Dermatology here.
Lasers target most pigmented lesions
May 1st 2004Washington - A number of different lasers covering a wide range of wavelengths can be used to treat a variety of pigmented lesions, but certain lasers work better than others and similarly, response varies by lesion type, said Jeffrey S. Dover, M.D., at the annual meeting of the American Academy of Dermatology here.
Inexpensive methods of sun protection
May 1st 2004Washington - Photoprotection has an important place in the prevention of skin cancer, but it should involve a multifactorial approach that puts inexpensive natural protection first, said Robin Marks, M.B.B.S, at the annual meeting of the American Academy of Dermatology.
Oral tazarotene shows sustained efficacy in psoriasis
May 1st 2004Washington - Oral tazarotene has sustained efficacy in the treatment of moderate to very severe plaque psoriasis with no cumulative toxicity. Alan Menter, M.D., presented data from a one-year, open-label study at the 62nd annual meeting of the American Academy of Dermatology.
Urea vehicle promotes tolerability of topical acne medication
May 1st 2004Washington, D.C. - A unique urea-containing vehicle appears to improve the tolerability of topical treatment with sodium sulfacetamide/sulfur in acne and rosacea patients with sensitive skin, according to the results of a randomized, double-blind, active comparator-controlled study presented by James J. Leyden, M.D., at the annual meeting of the American Academy of Dermatology.
FDA grants market approval for Hylaform
April 23rd 2004Inamed Corp. announced that the U.S. Food and Drug Administration has granted market approval for Hylaform, a hyaluronic acid-based dermal filler that is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds.
Sculptra gets backing of FDA panel to treat AIDS-related facial lipoatrophy
April 4th 2004Gaithersburg, Md. - The FDA General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee meeting on March 25 unanimously recommended approval of Sculptra for reconstructive purposes with lipoatrophy associated with HIV infection and treatment.